Cardiopulmonary effects of endothelin-1 in man.

[1]  B. Lipworth,et al.  Hypoxaemia and release of endothelin-1. , 1995, Thorax.

[2]  A. Davenport,et al.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub‐type , 1995, British journal of pharmacology.

[3]  B. Lipworth,et al.  Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans. , 1995, Thorax.

[4]  P. Nihoyannopoulos,et al.  Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? , 1994, European heart journal.

[5]  T. Rabelink,et al.  Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. , 1994, Kidney international.

[6]  B. Lipworth,et al.  Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. , 1994, Chest.

[7]  M. Maclean,et al.  Endothelin ETA- and ETB-Receptor‐Mediated Vasoconstriction in Rat Pulmonary Arteries and Arterioles , 1994, Journal of cardiovascular pharmacology.

[8]  W. Gaasch,et al.  Left Ventricular Diastolic Dysfunction and Heart Failure , 1994 .

[9]  Zile.  Hemodynamic loads and left ventricular diastolic function: Factors affecting the indices of isovolumetric and auxotonic relaxation , 1994 .

[10]  O. Kohmoto,et al.  Variable effects of endothelin-1 on [Ca2+]i transients, pHi, and contraction in ventricular myocytes. , 1993, The American journal of physiology.

[11]  D. Webb,et al.  The endothelin family of peptides: local hormones with diverse roles in health and disease? , 1993, Clinical science.

[12]  A. Weyman,et al.  Isovolumic relaxation time varies predictably with its time constant and aortic and left atrial pressures: implications for the noninvasive evaluation of ventricular relaxation. , 1992, American heart journal.

[13]  S. Scalvini,et al.  Right ventricular diastolic function in chronic obstructive lung disease. , 1992, The European respiratory journal.

[14]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[15]  D. Stewart,et al.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.

[16]  T. Lüscher,et al.  Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. , 1991, Circulation.

[17]  T. Horio,et al.  Plasma immunoreactive endothelin in essential hypertension. , 1990, The American journal of medicine.

[18]  W. Waldhäusl,et al.  Effect of endothelin-1 in man. , 1990, Circulation.

[19]  T. Evans,et al.  Endothelin-1 constricts human pulmonary resistance vessels in vitro. , 1989, British journal of pharmacology.

[20]  P. Grayburn,et al.  Effects of left ventricular preload and afterload on ascending aortic blood velocity and acceleration in coronary artery disease. , 1989, The American journal of cardiology.

[21]  C. Gomez-Sanchez,et al.  Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. , 1989, The Journal of clinical investigation.

[22]  M. Yanagisawa,et al.  Immunoreactive Endothelin‐1 in Plasma Detected by a Sandwich‐Type Enzyme Immunoassay , 1989, Journal of cardiovascular pharmacology.

[23]  H. Matsuoka,et al.  Endothelin: a new inhibitor of renin release. , 1988, Biochemical and biophysical research communications.

[24]  J. Madwed,et al.  Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs. , 1988, The American journal of physiology.

[25]  S. Warrington,et al.  Correction of systolic time intervals for heart rate: a comparison of individual with population derived regression equations. , 1988, British journal of clinical pharmacology.

[26]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[27]  J. Gardin,et al.  Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. , 1987, The American journal of cardiology.

[28]  Andrew,et al.  Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. , 1986, The Journal of clinical investigation.

[29]  M. Matsuda,et al.  Reliability of non-invasive estimates of pulmonary hypertension by pulsed Doppler echocardiography. , 1986, British heart journal.

[30]  J. E. Snyder,et al.  Noninvasive Evaluation of Left Ventricular Performance Based on Peak Aortic Blood Acceleration Measured with a Continuous-Wave Doppler Velocity Meter , 1986, Circulation.

[31]  M. Quiñones,et al.  Determination of parameters of left ventricular diastolic filling with pulsed Doppler echocardiography: comparison with cineangiography. , 1985, Circulation.

[32]  E. Bennett,et al.  Ascending aortic blood velocity and acceleration using Doppler ultrasound in the assessment of left ventricular function. , 1984, Cardiovascular research.

[33]  L L Huntsman,et al.  Noninvasive Doppler Determination of Cardiac Output in Man: Clinical Validation , 1983, Circulation.

[34]  S. Ahmed,et al.  Systolic Time Intervals as Measures of the Contractile State of the Left Ventricular Myocardium in Man , 1972, Circulation.

[35]  J. Bishop,et al.  The effects of synthetic hypertensin of the systemic and pulmonary circulations in man. , 1961, Clinical science.